Federal Register of Legislation - Australian Government

Primary content

PB 14 of 2012 Determinations/Health as made
This instrument adds five brand premiums, increases five brand premiums, decreases three premiums, changes the determined or claimed price with no change to the brand premium for four listed brands, and also removes one listed brand which ceases to have a therapeutic group premium.
Administered by: Health
Registered 30 Mar 2012
Tabling HistoryDate
Tabled HR08-May-2012
Tabled Senate10-May-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 14 of 2012

National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 2)1

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated                                          23 March 2012

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

         (1)           This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 2).

         (2)           This Instrument may also be cited as PB 14 of 2012.

2          Commencement

         (1)           This Instrument, except Schedule 2, commences on 1 April 2012.

         (2)           Schedule 2 to this Instrument commences on 1 April 2012, immediately after the application of section 99ADH of the National Health Act 1953 to the brand of pharmaceutical item ‘Nifedipine’ (listed drug) ‘Tablet 20 mg (controlled release)’ (form) ‘oral’ (manner of administration), ‘Adalat Oros 20 mg’ (listed brand).

3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

            Schedules 1 and 2 amend the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).



Schedule 1     Amendments commencing 1 April 2012

 

[1]       Schedule 1, entry for Bisacodyl

                omit from the column headed “Claimed Price”:          4.53        substitute:             4.64

[2]       Schedule 1, entry for Bleomycin

(a)           omit from the column headed “Determined Price”:     43.96     substitute:             36.93

(b)           omit from the column headed “Claimed Price”:          83.52     substitute:             70.15

[3]       Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg

(a)           omit from the column headed “Determined Price”:     12.13     substitute:             6.74

(b)           omit from the column headed “Claimed Price”:          13.83     substitute:             9.30

[4]       Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg

                omit from the column headed “Claimed Price”:          21.52     substitute:             22.39

[5]       Schedule 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg

(a)           omit from the column headed “Determined Price”:     35.70     substitute:             26.32

(b)           omit from the column headed “Claimed Price”:          37.57     substitute:             28.82

[6]       Schedule 1, entry for Eprosartan

substitute:

Eprosartan

Tablet 400 mg (as mesylate)

Oral

Teveten

28

7.37

8.89

 

Tablet 600 mg (as mesylate)

Oral

Teveten

28

18.44

20.18

[7]       Schedule 1, entry for Erythromycin in the form Capsule 250 mg (containing enteric coated pellets)

(a)           omit from the column headed “Determined Price”:     2.49        substitute:             3.71

(b)           omit from the column headed “Claimed Price”:          4.56        substitute:             5.78


[8]       Schedule 1, entry for Frusemide in the form Tablet 20 mg

(a)           omit from the column headed “Determined Price”:     1.07        substitute:             0.90

(b)           omit from the column headed “Claimed Price”:          1.90        substitute:             1.60

[9]       Schedule 1, entry for Frusemide in the form Tablet 40 mg

(a)           omit from the column headed “Determined Price”:     1.96        substitute:             1.65

(b)           omit from the column headed “Claimed Price”:          4.04        substitute:             3.39

[10]     Schedule 1, entry for Glipizide

(a)           omit from the column headed “Determined Price”:     4.40        substitute:             5.09

(b)           omit from the column headed “Claimed Price”:          7.73        substitute:             8.42

[11]     Schedule 1, after entry for Norfloxacin

insert in the columns in the order indicated:

Olmesartan

Tablet containing olmesartan medoxomil 20 mg

Oral

Olmetec

30

9.50

10.37

 

Tablet containing olmesartan medoxomil 40 mg

Oral

Olmetec

30

20.17

21.04

[12]     Schedule 1, entry for Oxazepam in the form Tablet 15 mg

(a)           omit from the column headed “Determined Price”:     0.93        substitute:             1.07

(b)           omit from the column headed “Claimed Price”:          3.27        substitute:             3.41

[13]     Schedule 1, entry for Ranitidine in the form Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL

(a)           omit from the column headed “Determined Price”:     6.65        substitute:             7.87

(b)           omit from the column headed “Claimed Price”:          7.61        substitute:             8.83


[14]     Schedule 1, after entry for Tamoxifen

insert in the columns in the order indicated:

Telmisartan

Tablet 40 mg

Oral

Micardis

28

6.74

8.48

 

Tablet 80 mg

Oral

Micardis

28

19.56

21.29

[15]     Schedule 2, after entry for Eprosartan in the form Tablet 400 mg (as mesylate)

insert in the columns in the order indicated:

 

Tablet 600 mg (as mesylate)

Oral

Teveten

Adverse effects occurring with all of the base-priced drugs.

Drug interactions occurring with all of the base-priced drugs. 

Drug interactions expected to occur with all of the base-priced drugs.

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

[16]     Schedule 2, after entry for Naratriptan

insert in the columns in the order indicated:

Olmesartan

Tablet containing olmesartan medoxomil 20 mg

Oral

Olmetec

Adverse effects occurring with all of the base-priced drugs.

Drug interactions occurring with all of the base-priced drugs. 

Drug interactions expected to occur with all of the base-priced drugs.

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 

Tablet containing olmesartan medoxomil 40 mg

Oral

Olmetec

Adverse effects occurring with all of the base-priced drugs.

Drug interactions occurring with all of the base-priced drugs. 

Drug interactions expected to occur with all of the base-priced drugs.

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 


[17]     Schedule 2, after entry for Ranitidine in the form Syrup 150 mg (as hydrochloride) per 10 mL, 300 mL

insert in the columns in the order indicated:

Telmisartan

Tablet 40 mg

Oral

Micardis

Adverse effects occurring with all of the base-priced drugs.

Drug interactions occurring with all of the base-priced drugs. 

Drug interactions expected to occur with all of the base-priced drugs.

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 

Tablet 80 mg

Oral

Micardis

Adverse effects occurring with all of the base-priced drugs.

Drug interactions occurring with all of the base-priced drugs. 

Drug interactions expected to occur with all of the base-priced drugs.

Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance. 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule 2     Nifedipine amendments

 

 

[1]    Schedule 1, entry for Nifedipine

omit:

 

Tablet 20 mg (controlled release)

Oral

Adalat Oros
20 mg

30

9.56

11.43

 

[2]    Schedule 2, omit entry for Nifedipine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.  See http://www.frli.gov.au.